Skip to main content
SpringerLink
Log in

Diagnosis and treatment in intestinal carcinoid tumors

  • Invited Commentary
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Conclusions

Patients with carcinoid tumors may present with a wide variety of symptoms depending on tumor localization, grade of malignancy, hormone production, and tumor symptoms. All of these factors must be taken into account in choice of the best-tailored treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moertel CG, Sauer WG, Docherty MB, Baggenstoss AH: Life history of the carcinoid tumor of the small intestine. Cancer 1961, 14:291–293.

    Google Scholar 

  2. Quaedvlieg PFHJ, Visser O, Lamers CBHW, et al.: Epidemiology and survival in patients with carcinoid disease in the Netherlands. Ann Oncol 2001, 12:1295–1300.

    Article  PubMed  CAS  Google Scholar 

  3. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97:934–959.

    Article  PubMed  Google Scholar 

  4. Hemminki K, Li: Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2001, 94:444–448.

    Article  PubMed  CAS  Google Scholar 

  5. Kaerlev L, Teglbjaerg PS, Sabroe S, et al.: Occupational risk factors for small bowel carcinoid tumor: a European population-based case-control study. J Occup Environ Med 2002, 44:516–522.

    Article  PubMed  CAS  Google Scholar 

  6. Capella C, Heitz PU, Hofler H, et al.: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995, 425:547–560.

    Article  PubMed  CAS  Google Scholar 

  7. Travis WD, Rush W, Flieder DB, et al.: Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22:934–944.

    Article  PubMed  CAS  Google Scholar 

  8. Van Eeden S, Quaedvlieg PF, Taal BG, et al.: Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 2002, 33:1126–1132.

    Article  PubMed  Google Scholar 

  9. Swain P: Wireless capsule endoscopy. Gut 2003, 52(Suppl)4:iv48-iv50.

    Article  PubMed  Google Scholar 

  10. Bajetta E, Ferrari L, Martinetti A, et al.: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999, 86:858–865.

    Article  PubMed  CAS  Google Scholar 

  11. Kema IP, de Vries EG, Schellings AM, et al.: Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 1992, 38:534–540.

    PubMed  CAS  Google Scholar 

  12. Nobels FR, Kwekkeboom DJ, Coopmans W, et al.: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622–2628.

    Article  PubMed  CAS  Google Scholar 

  13. Faiss S, Pape UF, Bohmig M, et al.: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003, 21:2689–2696.

    Article  PubMed  CAS  Google Scholar 

  14. Kulaksiz H, Eissele R, Rossler D, et al.: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002, 50:52–60.

    Article  PubMed  CAS  Google Scholar 

  15. Hoefnagel CA: Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994, 21:561–581.

    PubMed  CAS  Google Scholar 

  16. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H: Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 11In-pentetreotide in carcinoid tumours. Eur J Cancer 1996, 32A:1924–1932.

    Article  PubMed  CAS  Google Scholar 

  17. Zuetenhorst JM, Hoefnageli CA, Boot H, et al.: Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002, 23:735–741.

    Article  PubMed  CAS  Google Scholar 

  18. Ross EM, Roberts WC: The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985, 79:339–354.

    Article  PubMed  CAS  Google Scholar 

  19. Connolly HM, Crary JL, McGoon MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581–588.

    Article  PubMed  CAS  Google Scholar 

  20. Zuetenhorst JM, Bonfrer JMG, Korse CM, et al.: Carcinoid heart disease; the role of urinary 5-HIAA excretion and plasma levels of ANP, TGF-b and FGF. Cancer 2003, 97:1609–1615.

    Article  PubMed  CAS  Google Scholar 

  21. Zuetenhorst JM, Korse CM, Bonfrer JMG, Taal BG: The role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004, 90:2073–2079.

    PubMed  CAS  Google Scholar 

  22. Gupta S, Yao JC, Ahrar K, et al.: Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003, 9:261–267.

    Article  PubMed  Google Scholar 

  23. Wong SL, Edwards MJ, Chao C, et al.: Radiofrequency ablation for unresectable hepatic tumors. Am J Surg 2001, 182:552–557.

    Article  PubMed  CAS  Google Scholar 

  24. Hellman P, Ladjevardi S, Skogseid B, et al.: Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002, 26:1052–1056.

    Article  PubMed  Google Scholar 

  25. Taal BG, Hoefnagel CA, Valdes Olmos RA, et al.: Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996, 14:1829–1838.

    PubMed  CAS  Google Scholar 

  26. Taal BG, Hoefnagel CA, Boot H, et al.: Improved effect of 131I-MIBG treatment by predosing with non-radiobaled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 2000, 11:1437–1443.

    Article  PubMed  CAS  Google Scholar 

  27. Zuetenhorst JM, Valdes Olmos, Muller M, et al.: Interferon and MIBG combinations in the treatment of metastatic carcinoid tumours. Endocr Relate Cancer 2004, 11:553–561.

    Article  CAS  Google Scholar 

  28. Kwekkeboom DJ, Bakker WH, Kam BL, et al.: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003, 30:417–422.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, Amsterdam, CX, Netherlands

    Babs G. Taal MD, PhD

Authors
  1. Babs G. Taal MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taal, B.G. Diagnosis and treatment in intestinal carcinoid tumors. Curr Gastroenterol Rep 7, 1–3 (2005). https://doi.org/10.1007/s11894-005-0057-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-005-0057-2

Keywords

Search

Navigation